3 Small Cap Cancer Stocks With Upcoming Catalysts [View article]
Any concern over the very large outstanding share position of ONCS? I am guessing that without huge data upside beat that a reverse split of say 1 to 10 would be in order? Maybe with great data and a large infusion of cash from a potential partner might avoid that scenario. I do like the overall potential though.
With all due respect to Mannkind shareholders, while I do feel that their inhale insulin med (A) will likely be an improvement over Exubera, I just have my doubt that it will sell that well in the market, with SQ insulin injection really not that bad now with small guage needles... and the perception of inhale as to lung function problems could still be blown out of proportion, and now so many new drugs on the market. The market cap of MNKD is already very high, before approval and before even the clinical study not completed.
Can Monsanto Harvest More Shareholder Value? [View article]
Hey Mr. ### poster, If you don't like it so much then why do you waste your time to make up a new ID and post one time??? Yep, here we go again, another loon bashing Monsanto and using the 'evil' word too...lol. So, I guess every new biotech innovation that helps save lives by increasing food supply (that is proven safe) and others that help extend lives from dying of cancer and other major diseases is also 'evil'? - say it ain't so!
Durect: Pfizer Hints At Progress With Remoxy [View article]
What a poor downgrade by street dot com writer. (I am hearing he has made many similar poor downgrades of companies that are as high or higher than 10X of when he did so.) Downgrade makes no sense, because most with common sense looking at such a small biotech with huge potential are very forward thinking instead of looking at where the company has come from, or how much it is up this year. I bet any big drop is bought up and the price will rise much higher.
Undue Pressure On Trius Creates An Entrance Point [View article]
I would not be too concerned about the low price at this time. If it stays anywhere near this price prior to the drug approved and no takeover, that will be a wonderful thing for those of us that know the true potential value of the company.
License To IL-12: Finding A Potentially New Therapeutic Window [View instapost]
Nice article doc - I think that with ONCS, some think that since the stock is so cheap, it must be they are an unproven company and maybe suspect(not my opinion). And with the immunopulse/electro tx, they may think that it sounds odd and maybe an unusual type of treatment. But it makes sense to me the concept and that evidence thus far, especially if one realizes that due to the immunopulse addition, they are able to use 'less' of a IL-12 dose, correct? I doubt they just make that up to impress people. It will be interesting to see how the data in the 3 phase II trials turn out this year, and if there is likely confirmation the price should more than double from here...imo. Also to note, I think they are the only company working on clinical trials on merkel cell carcinoma. I also like the potential in ZIOP, but we may not find out any more good news for some time, unless we see some big insider buys of late.
The Crazy Thing About The 2008-2009 Stock Market Crash [View article]
Even though JNJ & PEP have risen a lot, you don't worry about how far up it is gone, you look at the future, and the likelihood that it will still keep going up, maybe not as fast, but they will keep going up.
Qualcomm: Understanding The Risks Before You Buy [View article]
More analysis paralysis. I thought Qualcomm explained things quite well, in that different markets go up and down with demand or similar words. The emerging markets were doing better in what they wanted with less costly chips while the developed markets were lighter. And even if margins were slightly off, one would think that QCOM would still lead and would definitely not be the first to lose much business. In other words, if there are to be less costly phones and more cheaper phones in Asia, Qualcomm still wins or leads. Reminds me of the drug store growth....the one who does have the most stores and can cut costs will likely lead, while it may take longer for a smaller less efficient company to even catch up in the least, such as RAD. And even if they do catch up and are successful, the leaders still are the real leaders. So maybe competition is a good thing!
Thanks Ashraf. One PR mentioned competition in Asia. Is that not in the low end space where they are attempting to move in more, and not that big a deal, since they should be able to gain share with what they can offer at the lower cost, they have talked about since the last QTR CC/other tech conference? Like yourself, I bought more, thinking the AH selling fiasco is way overdone on analysis paralysis, or to pressure losses in call options.
Qualcomm Earnings In Line - Doubling My Position [View article]
Looks like analysis paralysis as panicky longs sell when they should buy more or hold on. The earnings were great and the 'yearly' guidance was raised. They are treating this stock worse than Intel has been treated on a big miss, in after hours. Just bizarre! The price should definitely rebound tomorrow, or I will definitely double down myself.
Robert Half International Management Discusses Q1 2013 Results - Earnings Call Transcript [View article]
Price drop is ridiculous! RHI beat on what they reported one year ago, and have much room to grow. Second half of year will be much better and definitely a nice price to add at after a nearly 10% drop. I bet smart money is buying hand over fist right now!
Blackstone (BX -0.8%) reverses a big premarket move higher, perhaps as COO Tony James tells reporters in a pre-CC interview he sees a "spring swoon" for the economy and growth "not exactly around the corner." He sees "vast potential" as high net worth individuals - whose assets exceed those of institutions - are "way underrepresented" in the P-E space, and applauds retail offerings by CG and KKR. [View news story]
This is the company to own in the space, for strong performance and takeout potential well over GS and BAC or anyone...imo.
I am liking AVEO more and more, and got very long ACAD due to the huge potential there. Funny to see a few ignorant people on twitter say they want to short that 'turd' - as if! - where do those nuts come from? Mars?....lol.
AVEO Poised To Move Higher Before FDA Adcomm Catalyst, Obamacare And Platform Potential [View article]
Funny, so much selling at $7.60 for some people happy to take that quite minor short term gain, when I have a feeling that the price will go much higher before adcom and even after.
3 Small Cap Cancer Stocks With Upcoming Catalysts [View article]
Trius Patent Intrigues Investors, And Perhaps Cubist Pharmaceuticals [View article]
MannKind Corporation's CEO Discusses Q1 2013 Results - Earnings Call Transcript [View article]
Can Monsanto Harvest More Shareholder Value? [View article]
Durect: Pfizer Hints At Progress With Remoxy [View article]
Undue Pressure On Trius Creates An Entrance Point [View article]
License To IL-12: Finding A Potentially New Therapeutic Window [View instapost]
The Crazy Thing About The 2008-2009 Stock Market Crash [View article]
Qualcomm: Understanding The Risks Before You Buy [View article]
Qualcomm: What The Heck Happened? [View article]
Qualcomm Earnings In Line - Doubling My Position [View article]
Robert Half International Management Discusses Q1 2013 Results - Earnings Call Transcript [View article]
Blackstone (BX -0.8%) reverses a big premarket move higher, perhaps as COO Tony James tells reporters in a pre-CC interview he sees a "spring swoon" for the economy and growth "not exactly around the corner." He sees "vast potential" as high net worth individuals - whose assets exceed those of institutions - are "way underrepresented" in the P-E space, and applauds retail offerings by CG and KKR. [View news story]
Thursday's BioPharma Trade Movers [View article]
AVEO Poised To Move Higher Before FDA Adcomm Catalyst, Obamacare And Platform Potential [View article]